XERS [NASD]
Xeris Biopharma Holdings, Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own2.70% Shs Outstand135.03M Perf Week-19.01%
Market Cap269.34M Forward P/E- EPS next Y-0.48 Insider Trans2.45% Shs Float132.05M Perf Month-19.01%
Income-138.00M PEG- EPS next Q-0.25 Inst Own41.10% Short Float4.10% Perf Quarter-12.50%
Sales63.50M P/S4.24 EPS this Y27.30% Inst Trans23.76% Short Ratio2.99 Perf Half Y-9.26%
Book/sh0.71 P/B2.76 EPS next Y51.80% ROA-59.70% Target Price6.25 Perf Year-40.61%
Cash/sh0.96 P/C2.04 EPS next 5Y- ROE-264.00% 52W Range1.25 - 4.98 Perf YTD-33.11%
Dividend- P/FCF- EPS past 5Y-18.30% ROI-62.80% 52W High-61.04% Beta1.61
Dividend %- Quick Ratio2.40 Sales past 5Y115.20% Gross Margin72.00% 52W Low55.20% ATR0.21
Employees294 Current Ratio2.70 Sales Q/Q169.50% Oper. Margin- RSI (14)42.06 Volatility7.96% 11.47%
OptionableYes Debt/Eq1.43 EPS Q/Q16.90% Profit Margin- Rel Volume0.35 Prev Close1.96
ShortableYes LT Debt/Eq1.43 EarningsMay 11 BMO Payout- Avg Volume1.81M Price1.94
Recom1.70 SMA20-8.92% SMA50-19.15% SMA200-17.03% Volume500,030 Change-1.02%
Apr-28-22Initiated Craig Hallum Buy $6.50
Nov-17-21Initiated SVB Leerink Outperform $6
Oct-29-21Initiated H.C. Wainwright Buy $4
Apr-07-21Resumed RBC Capital Mkts Outperform $11
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
May-12-22 04:02PM  
May-11-22 07:00AM  
May-04-22 08:00AM  
Mar-23-22 10:34AM  
Mar-16-22 07:00AM  
Mar-10-22 07:00AM  
06:55AM  
Mar-04-22 07:00AM  
Mar-01-22 03:00PM  
Feb-09-22 07:00AM  
Jan-31-22 07:00AM  
Jan-13-22 08:55AM  
Jan-07-22 10:13AM  
Jan-06-22 07:00AM  
Jan-03-22 07:00AM  
Dec-31-21 03:10PM  
01:42PM  
12:51PM  
08:52AM  
Dec-30-21 04:30PM  
Dec-16-21 07:00AM  
Dec-06-21 08:34AM  
Nov-18-21 08:30AM  
Nov-10-21 07:00AM  
Nov-02-21 07:30AM  
Nov-01-21 03:02PM  
Oct-29-21 12:38PM  
Oct-25-21 07:30AM  
Oct-05-21 04:05PM  
04:01PM  
Oct-04-21 10:49AM  
Oct-01-21 04:05PM  
Sep-22-21 11:37AM  
Sep-17-21 08:00AM  
Sep-15-21 07:38AM  
Sep-14-21 04:05PM  
Sep-08-21 04:01PM  
Sep-07-21 04:05PM  
Sep-01-21 07:30AM  
Aug-31-21 07:30AM  
Aug-30-21 07:30AM  
07:30AM  
Aug-25-21 07:02AM  
Aug-23-21 03:40PM  
12:01PM  
08:00AM  
06:54AM  
Aug-19-21 08:00AM  
Aug-13-21 08:00AM  
Aug-11-21 04:05PM  
Aug-08-21 04:06AM  
Aug-05-21 09:15AM  
07:00AM  
Jul-29-21 04:05PM  
08:30AM  
Jul-28-21 04:15PM  
Jul-19-21 09:53AM  
08:00AM  
Jul-02-21 04:05PM  
Jun-29-21 10:15AM  
Jun-28-21 10:15AM  
Jun-16-21 08:32AM  
Jun-15-21 07:56AM  
Jun-05-21 03:55PM  
Jun-04-21 07:00PM  
Jun-01-21 06:20PM  
May-31-21 08:30PM  
May-28-21 06:01PM  
May-27-21 11:45AM  
May-25-21 11:13AM  
10:42AM  
May-24-21 06:30PM  
04:58PM  
12:43PM  
07:57AM  
07:28AM  
07:00AM  
06:55AM  
05:46AM  
May-17-21 08:20AM  
May-13-21 12:11PM  
07:00AM  
May-10-21 04:05PM  
May-06-21 04:05PM  
08:00AM  
Apr-29-21 05:05PM  
04:05PM  
Apr-28-21 08:08AM  
Apr-12-21 12:23PM  
Apr-01-21 04:05PM  
Mar-23-21 12:22PM  
09:14AM  
Mar-14-21 08:22PM  
Mar-12-21 05:35AM  
05:35AM  
Mar-11-21 07:00AM  
Mar-10-21 12:00PM  
02:35AM  
02:35AM  
Mar-09-21 08:15AM  
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Edick Paul RSee RemarksMay 12Buy1.40100,000140,3801,508,064May 13 04:19 PM
PRESTRELSKI STEVENChief Scientific OfficerFeb 22Option Exercise0.6911,2287,747581,008Feb 24 04:28 PM
PRESTRELSKI STEVENChief Scientific OfficerFeb 22Sale2.4211,22827,158569,780Feb 24 04:28 PM
Edick Paul RSee RemarksNov 15Buy2.2820,00045,66433,430Nov 16 04:25 PM
Shannon John Patrick JrSee RemarksNov 12Buy2.1060,000126,000363,829Nov 12 05:12 PM
Shannon John Patrick JrSee RemarksNov 11Buy2.0940,00083,500303,829Nov 12 05:12 PM
Edick Paul RSee RemarksNov 11Buy2.08200,000415,760808,064Nov 12 05:09 PM
Pieper StevenSee RemarksNov 10Buy2.0025,00049,918183,108Nov 12 05:06 PM